alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### WAHL et al., Respondents, v. CORNING, Appellant.

(Supreme Court, Appellate Division, Fourth Department.

March 16, 1905.)

Action by John Wahl and another against Anna Corning.

PER CURIAM.

Motion to dismiss appeal granted, unless the appellant, on or before April 15, 1905, file and serve the printed papers on appeal, as provided by rule 41, in which event said motion is denied; and, in case said printed papers are not served and filed as above provided, upon filing due proof of such default, the respondent may enter an order dismissing said appeal absolutely, with costs, without further notice.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-1997
<PERIOD-END>                               SEP-30-1996
<CASH>                                         551,384
<SECURITIES>                                         0
<RECEIVABLES>                                  521,932
<ALLOWANCES>                                         0
<INVENTORY>                                  1,284,259
<CURRENT-ASSETS>                             3,461,630
<PP&E>                                       4,758,761
<DEPRECIATION>                               3,587,460
<TOTAL-ASSETS>                               5,180,021
<CURRENT-LIABILITIES>                        1,722,566
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        16,934
<OTHER-SE>                                   1,156,401
<TOTAL-LIABILITY-AND-EQUITY>                 5,180,021
<SALES>                                              0
<TOTAL-REVENUES>                               954,187
<CGS>                                                0
<TOTAL-COSTS>                                  754,610
<OTHER-EXPENSES>                               229,443
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              59,960
<INCOME-PRETAX>                               (89,826)
<INCOME-TAX>                                    35,930
<INCOME-CONTINUING>                           (53,896)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (53,896)
<EPS-PRIMARY>                                    (.04)
<EPS-DILUTED>                                    (.04)
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
COMPANY'S  FORM 10-Q FOR THE NINE MONTH  PERIOD  ENDED  AUGUST  30,  1998 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                              Nov-29-1998
<PERIOD-START>                                 Dec-01-1997
<PERIOD-END>                                   Aug-30-1998
<CASH>                                         $102,551
<SECURITIES>                                   $0
<RECEIVABLES>                                  $6,082,536
<ALLOWANCES>                                   $0
<INVENTORY>                                    $17,874,128
<CURRENT-ASSETS>                               $25,830,326
<PP&E>                                         $56,332,366
<DEPRECIATION>                                 $26,500,091
<TOTAL-ASSETS>                                 $59,451,482
<CURRENT-LIABILITIES>                          $18,534,672
<BONDS>                                        $0
<PREFERRED-MANDATORY>                          $0
<PREFERRED>                                    $0
<COMMON>                                       $392,732
<OTHER-SE>                                     $14,167,595
<TOTAL-LIABILITY-AND-EQUITY>                   $59,451,482
<SALES>                                        $116,296,764
<TOTAL-REVENUES>                               $116,296,764
<CGS>                                          $70,211,045
<TOTAL-COSTS>                                  $70,211,045
<OTHER-EXPENSES>                               $3,445,472
<LOSS-PROVISION>                               $0
<INTEREST-EXPENSE>                             $1,386,393
<INCOME-PRETAX>                                $(745,089)
<INCOME-TAX>                                   $0
<INCOME-CONTINUING>                            $(745,089)
<DISCONTINUED>                                 $0
<EXTRAORDINARY>                                $0
<CHANGES>                                      $0
<NET-INCOME>                                   $(745,089)
<EPS-PRIMARY>                                  (0.04)
<EPS-DILUTED>                                  (0.04)
        



</TABLE>
January 10, 2011

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Page 12 

Table 7. Antiretroviral Components Not Recommended as Initial Therapy

 (Updated December 1, 2009)

ARV Drugs or Components

(in alphabetical order) Reasons for NOT recommending as initial therapy

ABC/3TC/ZDV (coformulated) as tripleNRTI combination regimen (BI)

• Inferior virologic efficacy

ABC + 3TC + ZDV + TDF as quadrupleNRTI combination (BI)

• Inferior virologic efficacy

ABC + ddI (BIII) • Insufficient data in ART-naïve patients

ABC + TDF (BIII) • Insufficient data in ART-naïve patients

DRV (unboosted) • Use without RTV has not been studied

DLV (BII) • Inferior virologic efficacy

• Inconvenient (three times daily) dosing

ddI + TDF (BII) • High rate of early virologic failure

• Rapid selection of resistance mutations

• Potential for immunologic nonresponse/CD4 T-cell decline

• Increased ddI drug exposure and toxicities

T-20 (BIII) • No clinical trial experience in ART-naïve patients

• Requires twice-daily subcutaneous injections

ETR (BIII) • Insufficient data in ART-naïve patients

IDV (unboosted) (BIII) • Inconvenient dosing (three times daily with meal restrictions)

• Fluid requirement

IDV (RTV-boosted) (BIII) • High incidence of nephrolithiasis

NFV (BI) • Inferior virologic efficacy

• High incidence of diarrhea

RTV as sole PI (BIII) • High pill burden

• Gastrointestinal intolerance

SQV (unboosted) (BI) • Inferior virologic efficacy

d4T + 3TC (BI) • Significant toxicities including lipoatrophy; peripheral 

neuropathy; and hyperlactatemia, including symptomatic and lifethreatening lactic acidosis, hepatic steatosis, and pancreatitis

TPV (ritonavir-boosted) (BI) • Inferior virologic efficacy

Acronyms: 3TC = lamivudine, ABC = abacavir, ARV = antiretroviral, d4T = stavudine, ddI = didanosine, DLV = delavirdine, DRV = darunavir, ETR = etravirine; 

IDV = indinavir, IDV/r = ritonavir-boosted indinavir, NFV = nelfinavir, NRTI = nucleoside reverse transcriptase inhibitor, RTV = ritonavir, SQV = sacquinavir, T20 = enfuvirtide, TDF = tenofovir, TPV = tipranavir, ZDV = zidovudine
**EXHIBIT 31.2**

 

**CERTIFICATION PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

 

I, A. P. Kimble, certify that: 

 

1. I have reviewed this annual report on Form 10-K of North Pittsburgh Systems, Inc.; 

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suchstatements were made, not misleading with respect to the period covered by this report; 

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of theregistrant as of, and for, the periods presented in this report; 

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: 

 

(a) Designed such disclosure controls and procedures, orcaused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared; 

 

(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the endof the period covered by this report based on such evaluation; and 

 

(c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscalquarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internalcontrol over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function): 

 

(a) all significant deficiencies and material weaknesses in the design or operation of internal control overfinancial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and 

 

(b) any fraud, whether or not material, that involves management or other employees who have a significantrole in the registrant’s internal control over financial reporting. 

 

Date: March 15, 2004
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE LIFECORE
BIOMEDICAL, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE
MONTHS ENDED MARCH 31, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          JUN-30-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                       1,378,000
<SECURITIES>                                25,288,000
<RECEIVABLES>                                3,452,000
<ALLOWANCES>                                   328,000
<INVENTORY>                                  9,372,000
<CURRENT-ASSETS>                            30,385,000
<PP&E>                                      20,562,000
<DEPRECIATION>                               5,224,000
<TOTAL-ASSETS>                              61,417,000
<CURRENT-LIABILITIES>                        2,636,000
<BONDS>                                      6,835,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       122,000
<OTHER-SE>                                  51,824,000
<TOTAL-LIABILITY-AND-EQUITY>                61,417,000
<SALES>                                     12,863,000
<TOTAL-REVENUES>                            12,863,000
<CGS>                                        6,362,000
<TOTAL-COSTS>                               15,039,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             522,000
<INCOME-PRETAX>                            (1,170,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,170,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,170,000)
<EPS-PRIMARY>                                    (.10)
<EPS-DILUTED>                                    (.10)
        

</TABLE>
Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Constar International Inc. (the Company) on Form 10-Q for the period ending March 31, 2007, as filed with the Securities and Exchange Commission on the date
hereof (the Report), I, Michael J. Hoffman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.



|                                                        
|--------------------------------------------------------
|/s/ MICHAEL J. HOFFMAN                                  
|Michael J. Hoffman President and Chief Executive Officer

May 15, 2007
#### § 942.824 Special performance standards—Mountaintop removal.

Part 824 of this chapter, *Special Permanent Program Performance Standards—Mountaintop Removal,* shall apply to any person who conducts surface coal mining and reclamation operations constituting mountaintop removal.
<TABLE> <S> <C>

<ARTICLE>                              5
<MULTIPLIER>                           1

<S>                                                      <C>
<PERIOD-TYPE>                                            12-Mos
<FISCAL-YEAR-END>                                        Dec-31-1996
<PERIOD-START>                                           Jan-01-1996
<PERIOD-END>                                             Dec-31-1996
<CASH>                                                       158,648
<SECURITIES>                                                       0
<RECEIVABLES>                                                 13,205
<ALLOWANCES>                                                       0
<INVENTORY>                                                        0
<CURRENT-ASSETS>                                             199,076
<PP&E>                                                     9,777,728
<DEPRECIATION>                                             2,529,208
<TOTAL-ASSETS>                                             7,452,392
<CURRENT-LIABILITIES>                                         66,479
<BONDS>                                                            0
<PREFERRED-MANDATORY>                                              0
<PREFERRED>                                                        0
<COMMON>                                                           0
<OTHER-SE>                                                 7,385,913
<TOTAL-LIABILITY-AND-EQUITY>                               7,452,392
<SALES>                                                            0
<TOTAL-REVENUES>                                           1,488,341
<CGS>                                                              0
<TOTAL-COSTS>                                              1,001,727
<OTHER-EXPENSES>                                                   0
<LOSS-PROVISION>                                                   0
<INTEREST-EXPENSE>                                                 0
<INCOME-PRETAX>                                              486,614
<INCOME-TAX>                                                       0
<INCOME-CONTINUING>                                          486,614
<DISCONTINUED>                                                     0
<EXTRAORDINARY>                                                    0
<CHANGES>                                                          0
<NET-INCOME>                                                 486,614
<EPS-PRIMARY>                                                  43.59
<EPS-DILUTED>                                                  43.59
<FN>
The earnings per share data noted above refers to
net income per limited partnership unit.
</FN>


</TABLE>
#### § 942.707 Exemption for coal extraction incident to government-financed highway or other construction.

Part 707 of this chapter, *Exemption for Coal Extraction Incident to Government-Financed Highway or Other Construction,* shall apply to surface coal mining and reclamation operations.
#### The People of the State of Illinois ex rel. Margaret A. Flynn, appellee, v. Francis X. Busch et al., appellants.

Gen. No. 29,484.

Mandamus to compel payment to petitioner of a certain sum from the Firemen’s Pension Fund. Writ issued. Appeal from the Circuit Court of Cook county; the Hon. Philip L. Sullivan, Judge, presiding. Heard in the second division of this court for the first district at the October term, 1924.

Reversed and remanded with directions.

Opinion filed March 3, 1925.

Francis X. Busch, Corporation Counsel, for appellants; Albert H. Veeder, Assistant Corporation Counsel, of counsel.

Michael F. Girten, for appellee.

Mr. Justice Gridley

delivered the opinion of the court.
#### The People of the State of New York, Respondent, v Clifford S. Crogan, Appellant.

[833 NYS2d 421]

Appeal from a judgment of the Niagara County Court (Sara S. Sperrazza, J.), rendered June 21, 2004. The judgment revoked defendant’s sentence of probation and imposed a sentence of imprisonment.

It is hereby ordered that the judgment so appealed from be and the same hereby is unanimously affirmed. Present—Gorski, J.P, Lunn, Fahey, Green and Pine, JJ.
<PAGE>

                                                                    EXHIBIT 99.2


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Annual Report of Sionix Corporation (the
"Company") on Form 10-KSB for the period ending September 30, 2002, as filed
with the Securities and Exchange Commission (the "Report"), the undersigned,
Robert McCray, Chief Financial Officer of the Company, certifies to the best of
his knowledge, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, that:

         (1)      The Report fully complies with the requirements of section
                  13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2)      The information contained in the Report fairly presents, in
                  all material respects, the financial condition and results of
                  operations of the Company.

         Date: December 10, 2002          /s/ Robert McCray
                                          --------------------------------------
                                          Robert McCray, Chief Financial Officer


         This certification accompanies this Report pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended.



                                       44
§ 762.13 Land exempt from designation as unsuitable for surface coal mining operations. The requirements of this part do not apply to— ( a ) Lands on which surface coal mining operations were being conducted on the date of enactment of the Act;
( b ) Lands covered by a permit issued under the Act; or
( c ) Lands where substantial legal and financial commitments in surface coal mining operations were in existence prior to January 4, 1977.
Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Constar International Inc. (the Company) on Form 10-Q for the period ending June 30, 2009, as filed with the Securities and Exchange Commission on the date
hereof (the Report), I, Michael J. Hoffman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.



|                                     
|-------------------------------------
|/s/ MICHAEL J. HOFFMAN               
|Michael J. Hoffman                   
|President and Chief Executive Officer

August 14, 2009
### §300303. Council

In this division, the term "Council" means the Advisory Council on Historic Preservation established by section 304101 of this title.

(Pub. L. 113–287, §3, Dec. 19, 2014, 128 Stat. 3188.)

| Revised Section | Source (U.S. Code) | Source (Statutes at Large) |
| --- | --- | --- |
| 300303 | 16 U.S.C. 470w(16). | Pub. L. 89–665, title III, §301(16), as added Pub. L. 102–575, title XL, §4019(a), Oct. 30, 1992, 106 Stat. 4764. |

Section
#### § 77.906 Trailing cables supplying power to low-voltage mobile equipment; ground wires and ground check wires.

On and after September 30, 1971, all trailing cables supplying power to portable or mobile equipment from low-voltage three-phase resistance grounded power systems shall contain one or more ground conductors having a cross-sectional area of not less than one-half the power conductor. Such trailing cables shall include an insulated conductor for the ground continuity check circuit except where a no less effective device has been approved by the Secretary to assure continuity. Splices made in low-voltage trailing cables shall provide continuity of all components.